Table 2b.

Group differences of kynurenine metabolites or ratios (ANCOVA) with age and gender as standard cofactors. Current psychotropic medication was used as cofactor in the ANCOVAs of SCZ-BD and acute-stable patients.

	Controls (n = 185)	All patients (n = 507)			Acute patients	Stable patients			BD	SCZ
	Mean (SD)	Mean (SD)	F	FDR P-value	Mean (SD)	Mean (SD)	F	FDR P-value	Mean (SD)	Mean (SD)	F	FDR P-value
TRP (uM)	63.22 (13.09)	58.46 (17.95)	9.04	.007	56.61 (17.34)	61.52 (18.55)	11.15	.005	58.82 (59.35)	59.35 (18.08)	.672	.649
KYN (uM)	2.43 (.55)	2.34 (.73)	5.11	.044	2.32 (.74)	2.38 (.71)	0.37	.542	2.41 (.67)	2.30 (.71)	4.77	.081
KA (nM)	68.71 (30.22)	63.83 (30.88)	5.83	.035	60.63 (31.34)	69.14 (29.42)	6.33	.045	65.71 (32.28)	64.23 (30.23)	0.16	.692
QUINA (nM)	11.43 (5.54)	9.72 (5.40)	15.23	.001	8.35 (4.91)	11.98 (6.85)	30.77	.001	10.03 (5.62)	10.08 (6.28)	1.52	.400
XA (nM)	314.96 (53.04)	286.92 (65.30)	26.29	<.001	281.49 (66.75)	295.90 (61.96)	3.86	.092	295.43 (64.81)	287.72 (60.93)	0.20	.719
PICO (nM)	58.14 (20.39)	63.89 (27.79)	4.40	.057	62.72 (27.23)	65.85 (28.68)	1.19	.276	60.16 (24.00)	66.42 (29.16)	6.05	.078
QUINO (nM)	101.37 (40.38)	87.11 (46.75)	11.31	0.003	82.83 (47.82)	94.67 (43.96)	5.94	.034	93.87 (47.27)	85.77 (43.58)	1.17	.310
KYN/TRP	0.040 (0.011)	0.043 (0.017)	1.90	.231	0.044 (0.018)	.041 (.014)	6.24	.035	0.043 (.016)	0.041 (.016)	6.89	.098
KA/KYN	29.42 (14.78)	29.34 (16.65)	0.07	.788	28.26 (17.41)	31.11 (15.19)	2.00	.248	29.15 (17.29)	29.79 (15.42)	0.27	.833
XA/KYN	132.99 (28.17)	130.29 (36.24)	0.13	.791	130.11 (39.11)	130.57 (31.01)	0.02	.882	129.20 (33.98)	133.02 (36.04)	5.06	.091
QUINO/KA	1.96 (1.51)	1.76 (1.45)	1.06	.371	1.78 (1.72)	1.72 (1.37)	.103	.823	1.87 (1.76)	1.51 (1.49)	0.23	.774